

the
christopher
project

MDF FDA Workshop

Thursday, September 17, 2015

Presented by Katharine A. Hagerman, PhD

The Christopher Project

A comprehensive survey of patients and families about their experience in living with myotonic dystrophy.

Aims:

- Examine disease complexity
- Understand unmet needs
- Identify what matters most
- Improve health outcomes

The Christopher Project

Collaboration across North America:

- Patients and families
- National advocacy organizations
- Health care providers and disease experts

Partners:



MYOTONIC
DYSTROPHY
FOUNDATION

 Muscular
Dystrophy Canada

MDA
Fighting Muscle Disease



The Marigold Foundation
Creating Hope & Opportunity



STANFORD
SCHOOL OF MEDICINE



UNIVERSITY OF
ROCHESTER



The Christopher Project

Survey Distribution

- 3,967 surveys mailed out
- 1,433 received = 36% response rate


Over 100 questions on:

- Demographics
- Current Health
- Diagnostic Experience
- Information and Resources
- Physical Symptoms
- Health Care Experience
- Managing Daily Life
- Insurance

Administered under human subjects ethics
approval in U.S.A. and Canada

Christopher Project Respondents

Survey Question: What type of myotonic dystrophy do you have?



N=1,180 valid responses

- DM1 (n=457)
- cDM1
- DM2
- Unknown/unsure
- Omitted

Data Presented Today

457 respondents living with DM1:

- 78% report confirmed genetic diagnosis
- does not include congenital DM1

Topics:

- Demographic profile
- Symptom prevalence and impact
- Employment picture
- Understanding complexity
- Comparison with PRISM study

Demographic Profile

Christopher Project represents a diverse gender, age and geographic sample of myotonic dystrophy patients.

Characteristic	Value
# respondents	457
Male	39%
Female	61%
Mean age \pm SD	45.0 \pm 16.0
Mean age of onset \pm SD	27.2 \pm 14.9

Symptom Prevalence

Percentage of DM1 respondents who report that they experience the specific symptom:

Rank	Symptom	Christopher Project	PRISM Comparison*
1	Muscle weakness	96%	94% ^a
2	Daytime sleepiness	94%	88% ^b
3	Fatigue	93%	91% ^c
4	Myotonia	88%	90% ^d

*Corresponding PRISM Item:

a: Problems with hands or arms

b: Impaired sleep or daytime sleepiness

c: Fatigue

d: Myotonia

Top 4 Symptoms by Relative Impact

Rank	Symptom	Symptom Score (/3)
1	Muscle weakness	2.16
2	Fatigue	2.14
3	Daytime sleepiness	2.08
4	Myotonia	1.68

Christopher Project Symptom Rating Scale:

0: Have Symptom with NO Impact

1: Have Symptom with MINOR Impact

2: Have Symptom with MODERATE Impact

3: Have Symptom with MAJOR Impact

Employment Picture

Major challenges in obtaining and retaining employment*

DM1 respondents 21 through 65 years	n=390
Report being employed full-time	17.4%
Report being employed part-time	13.1%

Report being <i>“Unable to work due to DM”</i>	46.2%
--	-------

*U.S. Department of Labor; Bureau of Labor Statistics
<http://data.bls.gov/timeseries/LNS14000000>

Understanding Complexity

- Christopher Project data captures the variability, heterogeneity and severity of this complex disease
- Enables examination of differences, similarities and relationships among subgroups; examples:
 - Prevalence of muscle weakness, fatigue and myotonia vary significantly based on *current age*
 - Prevalence of daytime sleepiness is significantly higher for *age of onset* between 21-30 years of age
 - Impact of muscle weakness increases with *age* until 61+, when impact lessens
- Provides basis and insight for further research and therapeutic development

Christopher Project & PRISM

- Both studies capture and illuminate the experience of myotonic dystrophy patients and families
- Results between studies are highly comparable
- Christopher Project confirms and reinforces PRISM findings regarding symptom prevalence and relative impact

Summary

- Christopher Project highlights the value of patient reported outcomes while capturing extensive data on the patient and family experience
 - Heavy symptom burden: muscle weakness and sleep/fatigue issues are critical
 - Sufficiently powered to yield critical insight into complex disease presentation (heterogeneity, variability and progression)
 - Insight into numerous aspects of daily life
 - Confirms and reinforces other patient-reported findings

Overall study findings will be submitted for peer-reviewed publication in Q4 2015

Christopher Project data will be available to qualified parties upon request

Acknowledgements

Thank you to our 1,433 Survey Participants!

Christopher Project Team:

- Sarah Howe
- Don MacKenzie
- Diane Bade
- Cynthia Gagnon
- Chad Heatwole
- Sharon Hesterlee
- Sue McIntyre
- Marla Spiegel
- Eric Wang
- Jodi Wolff

Partners:

- MDF
- MDC
- MDA
- Stanford University
- University of Rochester
- GRIMN

Partners:



MYOTONIC
DYSTROPHY
FOUNDATION

 Muscular
Dystrophy Canada

MDA
Fighting Muscle Disease



The Marigold Foundation
Creating Hope & Opportunity

 STANFORD
SCHOOL OF MEDICINE

 UNIVERSITY OF
ROCHESTER

GRIMN